Arrowhead Pharmaceuticals Inc’s filing revealed that its Officer Myszkowski Kenneth Allen acquired Company’s shares for reported $0.76 million on Jul 10 ’25. In the deal valued at $19.04 per share,40,000 shares were bought.
Then, Anzalone Christopher Richard sold 50,800 shares, generating $583,692 in total proceeds. Upon selling the shares at $11.49, the Chief Executive Officer now owns 3,921,255 shares.
Before that, Anzalone Christopher Richard sold 50,000 shares. Arrowhead Pharmaceuticals Inc shares valued at $543,500 were divested by the Chief Executive Officer at a price of $10.87 per share. As a result of the transaction, Anzalone Christopher Richard now holds 3,972,055 shares, worth roughly $58.43 million.
Goldman initiated its Arrowhead Pharmaceuticals Inc [ARWR] rating to a Neutral in a research note published on June 05, 2024; the price target was $31. A number of analysts have revised their coverage, including BofA Securities’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. Citigroup began covering ARWR with “Neutral” recommendation on September 19, 2023. TD Cowen started covering the stock on July 21, 2023. It rated ARWR as “an Outperform”.
Price Performance Review of ARWR
On Monday, Arrowhead Pharmaceuticals Inc [NASDAQ:ARWR] saw its stock fall -12.23% to $14.71. Over the last five days, the stock has lost -20.96%. Arrowhead Pharmaceuticals Inc shares have fallen nearly -47.50% since the year began. Nevertheless, the stocks have fallen -21.76% over the past one year.
How much short interest is there in Arrowhead Pharmaceuticals Inc?
A steep rise in short interest was recorded in Arrowhead Pharmaceuticals Inc stocks on 2025-06-13, dropping by -0.56 million shares to a total of 12.68 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 13.24 million shares. There was a decline of -4.44%, which implies that there is a negative sentiment for the stock.
